Conference Coverage
Conference Coverage
Longer edoxaban may benefit cancer patients with distal DVT
“This is the first and only randomized trial to show the superiority of longer duration over shorter duration of anticoagulation therapy for...
Conference Coverage
Measures of PTH predict postthyroidectomy hypocalcemia
“This measure can serve as a guide for discharging patients the same day, with instructions to return if they develop any symptoms of hypocalcemia...
Conference Coverage
Triple therapy boosts anaplastic thyroid cancer survival
"The very long median overall survival in the study's neoadjuvant group is quite remarkable for a group of patients who used to have a very poor...
Conference Coverage
Therapeutic vaccine shows promise in treating lung cancer
“We realized that just half of patients really benefited from the vaccine: those who had previously responded to immunotherapy.”
Conference Coverage
Nivolumab/Ipillimumab combo demonstrates long-term efficacy in NSCLC
“Most importantly, approximately 50% of these patients that are alive at six years are also disease free, suggesting that we are indeed making a...
Conference Coverage
Proposed TNM update could shift staging for lung cancers
Lung cancers, particularly those with T1 disease, could be reclassified into a different overall stage if proposed adaptations to the N and M...
Conference Coverage
Neoadjuvant durvalumab does not affect surgical outcomes in NSCLC: Study
AEGEAN is one of the first studies looking at immune checkpoint inhibitors in the perioperative settings that demonstrated improved EFS and pCR...
Conference Coverage
Debate: Should smoldering myeloma be treated?
After hearing two experts debate the evidence at the SOHO annual meeting, an audience seemed swayed to treat high-risk myeloma patients.
Conference Coverage
Osimertinib plus chemo ups PFS, toxicity in first line
Combining osimertinib with chemotherapy improved progression-free survival in EGFR-mutated non–small cell lung cancer, new interim data show, but...
Conference Coverage
Safely skip PET2 after brentuximab in Hodgkin lymphoma?
Recent data presented at SOHO 2023 suggested that adding brentuximab vedotin to chemotherapy for Hodgkin lymphoma improves outcomes, even without...
Latest News
Can skin bleaching lead to cancer?
Prevalence of skin bleaching in several African countries ranged from 25% in Mali (based on a 1993 survey of 210 women) to a high of 79.25% in...